New drug combo aims to shrink stomach tumors before surgery

NCT ID NCT07595523

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new immunotherapy drug called iparomlimab tolvorlimab (QL1706) in 30 people with a specific type of locally advanced stomach cancer (MSI-H/dMMR). The drug is given before and after surgery to see if it can eliminate the tumor. The main goal is to see how many patients have no cancer cells left in their removed tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iparomlimab tolvorlimab (QL1706)
What this could lead to: If successful, this could provide a new treatment option for patients with a specific type of gastric cancer that doesn't respond well to standard chemotherapy.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to all patients. The drug can cause immune-related side effects, and it's not yet proven to be better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.